Literature DB >> 20035773

Cannabinoid receptor-mediated antinociception with acetaminophen drug combinations in rats with neuropathic spinal cord injury pain.

Aldric T Hama1, Jacqueline Sagen.   

Abstract

Pre-clinical evidence demonstrates that neuropathic spinal cord injury (SCI) pain is maintained by a number of neurobiological mechanisms, suggesting that treatments directed at several pain-related targets may be more advantageous compared to a treatment focused on a single target. The current study evaluated the efficacy of the non-opiate analgesic acetaminophen, which has several putative analgesic mechanisms, combined with analgesic drugs used to treat neuropathic pain in a rat model of below-level neuropathic SCI pain. Following an acute compression of the mid-thoracic spinal cord, rats exhibited robust hind paw hypersensitivity to innocuous mechanical stimulation. Fifty percent antinociceptive doses of gabapentin, morphine, tramadol or memantine were combined with an ineffective dose of acetaminophen; acetaminophen alone was not antinociceptive. The combination of acetaminophen with either tramadol or memantine resulted in an additive antinociceptive effect. Acetaminophen combined with either morphine or gabapentin, however, resulted in supra-additive (synergistic) efficacy. One of the analgesic mechanisms of acetaminophen is inhibiting the uptake of endocannabinoids from the extracellular space. Pre-treatment with AM251, a cannabinoid-1 receptor (CB1) antagonist, significantly diminished the antinociceptive effect of the acetaminophen + gabapentin combination. Pre-treatment with AM630, a cannabinoid-2 receptor (CB2) antagonist, did not have an effect on this combination. By contrast, both AM251 and AM630 reduced the efficacy of the acetaminophen + morphine combination. None of the active drugs alone were affected by either CB receptor antagonist. The results imply that modulation of the endocannabinoid system in addition to other mechanisms mediate the synergistic antinociceptive effects of acetaminophen combinations. Despite the presence of a cannabinoid mechanism, synergism was not present in all acetaminophen combinations. The combination of currently available drugs may be an appropriate option in ameliorating neuropathic SCI pain if single drug therapy is ineffective. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20035773      PMCID: PMC2826109          DOI: 10.1016/j.neuropharm.2009.12.010

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  80 in total

1.  Ultra-low dose ketamine and memantine treatment for pain in an opioid-tolerant oncology patient.

Authors:  Lucinda A Grande; Brendan R O'Donnell; Dermot R Fitzgibbon; Gregory W Terman
Journal:  Anesth Analg       Date:  2008-10       Impact factor: 5.108

2.  Sex- and age-dependent acetaminophen hepato- and nephrotoxicity in Sprague-Dawley rats: role of tissue accumulation, nonprotein sulfhydryl depletion, and covalent binding.

Authors:  J B Tarloff; E A Khairallah; S D Cohen; R S Goldstein
Journal:  Fundam Appl Toxicol       Date:  1996-03

3.  Antioxidative and hepatoprotective effects of magnolol on acetaminophen-induced liver damage in rats.

Authors:  Yung-Hsiang Chen; Feng-Yen Lin; Po-Len Liu; Yi-Tsau Huang; Jen-Hwey Chiu; Yi-Chun Chang; Kee-Ming Man; Chuang-Ye Hong; Yen-Yi Ho; Ming-Tsung Lai
Journal:  Arch Pharm Res       Date:  2009-03-13       Impact factor: 4.946

4.  Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.

Authors:  Victoria L Haller; David L Stevens; Sandra P Welch
Journal:  Eur J Pharmacol       Date:  2008-08-20       Impact factor: 4.432

5.  Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia.

Authors:  Christophe Mallet; Laurence Daulhac; Jérôme Bonnefont; Catherine Ledent; Monique Etienne; Eric Chapuy; Frédéric Libert; Alain Eschalier
Journal:  Pain       Date:  2008-05-15       Impact factor: 6.961

6.  The endocannabinoid system is modulated in response to spinal cord injury in rats.

Authors:  Daniel Garcia-Ovejero; Angel Arevalo-Martin; Stefania Petrosino; Fabian Docagne; Carlos Hagen; Tiziana Bisogno; Masahiko Watanabe; Carmen Guaza; Vincenzo Di Marzo; Eduardo Molina-Holgado
Journal:  Neurobiol Dis       Date:  2008-09-30       Impact factor: 5.996

Review 7.  Cancer pain and analgesia.

Authors:  Paul J Christo; Danesh Mazloomdoost
Journal:  Ann N Y Acad Sci       Date:  2008-09       Impact factor: 5.691

8.  The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors.

Authors:  D da Fonseca Pacheco; A Klein; A de Castro Perez; C M da Fonseca Pacheco; J N de Francischi; I D G Duarte
Journal:  Br J Pharmacol       Date:  2008-05-12       Impact factor: 8.739

9.  Behavioral characterization and effect of clinical drugs in a rat model of pain following spinal cord compression.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Brain Res       Date:  2007-09-16       Impact factor: 3.252

10.  Tramadol in neuropathic pain after spinal cord injury: a randomized, double-blind, placebo-controlled trial.

Authors:  Cecilia Norrbrink; Thomas Lundeberg
Journal:  Clin J Pain       Date:  2009 Mar-Apr       Impact factor: 3.442

View more
  13 in total

1.  Validity of acute and chronic tactile sensory testing after spinal cord injury in rats.

Authors:  Megan Ryan Detloff; Leslie M Clark; Karen J Hutchinson; Anne D Kloos; Lesley C Fisher; D Michele Basso
Journal:  Exp Neurol       Date:  2010-07-17       Impact factor: 5.330

2.  Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Brain Res       Date:  2011-07-26       Impact factor: 3.252

3.  Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.

Authors:  Weisi Fu; Bradley K Taylor
Journal:  Neurosci Lett       Date:  2015-04-03       Impact factor: 3.046

4.  Combinations of intrathecal gamma-amino-butyrate receptor agonists and N-methyl-d-aspartate receptor antagonists in rats with neuropathic spinal cord injury pain.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Eur J Pharmacol       Date:  2012-03-16       Impact factor: 4.432

5.  Acetaminophen modulation of hydrocodone reward in rats.

Authors:  Arbi Nazarian; Deepthi Are; John M Tenayuca
Journal:  Pharmacol Biochem Behav       Date:  2011-05-11       Impact factor: 3.533

6.  An insight into paracetamol and its metabolites using molecular docking and molecular dynamics simulation.

Authors:  Yuanqiang Wang; Weiwei Lin; Nan Wu; Xibing He; Junmei Wang; Zhiwei Feng; Xiang-Qun Xie
Journal:  J Mol Model       Date:  2018-08-18       Impact factor: 1.810

Review 7.  Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor.

Authors:  Craig T Hartrick; Richard J Rozek
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

8.  Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression.

Authors:  Hyangin Kim; Lucy Chen; Grewo Lim; Backil Sung; Shuxing Wang; Michael F McCabe; Gabriel Rusanescu; Liling Yang; Yinghong Tian; Jianren Mao
Journal:  J Clin Invest       Date:  2012-07-02       Impact factor: 14.808

Review 9.  Cannabinoid system and cyclooxygenases inhibitors.

Authors:  H Păunescu; O A Coman; L Coman; I Ghiţă; S R Georgescu; F Drăghia; I Fulga
Journal:  J Med Life       Date:  2011-02-25

10.  Combination Drug Therapy for Pain following Chronic Spinal Cord Injury.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Pain Res Treat       Date:  2012-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.